Updated:
Nightingale Health Plc
Nightingale Health Plc, founded in 2013 in Helsinki, Finland, grew out of research at the University of Oulu focused on NMR-based metabolomics.
Nightingale Health Plc
Nightingale Health Plc, founded in 2013 in Helsinki, Finland, grew out of research at the University of Oulu focused on NMR-based metabolomics. The company’s platform processes blood samples using nuclear magnetic resonance spectroscopy to quantify lipid, fatty acid, and amino acid concentrations, producing standardized risk biomarkers. Teemu Suna serves as CEO, and the firm went public on the Nasdaq First North Helsinki exchange in June 2021, raising €45 million in its IPO. The company targets three primary segments: insurance, clinical trials for pharmaceutical companies, and consumer wellness. Its risk prediction models, validated in large cohort studies such as the UK Biobank, assess likelihood of cardiometabolic and neurodegenerative diseases. Nightingale reports partnerships with insurers in Europe and Asia for underwriting and wellness programs, and has collaborated with pharmaceutical firms for patient stratification in drug development. Geographic focus spans Finland, the United Kingdom, and Japan. As of 2025, Nightingale Health employs approximately 100 people, with key operations in Helsinki and a subsidiary in Tokyo, Japan. In November 2024, the firm announced an integration with the Finnish national health data platform to offer risk screening to healthcare providers (per Nightingale Health press release, November 2024). The company does not disclose assets under management, as it is not an investment firm but a health technology company. Nightingale Health’s structural differentiator is its regulatory-approved biomarker platform that enables population-scale risk assessment from a single blood sample. This positions it as a data infrastructure provider rather than a conventional family office or fund, generating recurring revenue through licensing and test kits to enterprise clients.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Finland
City
Helsinki
Corporate office
Helsinki, Finland
Sector focus
Frequently asked questions
What is Nightingale Health's core technology?
Nightingale Health uses nuclear magnetic resonance spectroscopy to analyze blood samples, measuring over 250 lipid, fatty acid, and amino acid biomarkers. The platform generates standardized risk scores for diseases including cardiovascular disease, type 2 diabetes, and dementia. This data is used by insurers for underwriting, by pharmaceutical companies for clinical trial stratification, and by consumers directly (per public record).
Who leads Nightingale Health?
Teemu Suna serves as the CEO of Nightingale Health Plc. The company was founded by researchers from the University of Oulu, including Peter Würtz and others. As a publicly listed entity on the Nasdaq First North Helsinki exchange, its leadership is subject to standard corporate governance disclosures (per the firm's communications).
Is Nightingale Health a family office or an investment vehicle?
No — Nightingale Health Plc is a publicly traded health analytics company. It does not manage capital for external investors or families. The firm generates revenue through commercial contracts with insurance companies, pharmaceutical firms, and health systems. It is listed on the Nasdaq First North Helsinki exchange (per public record).
What markets does Nightingale Health operate in?
The company is headquartered in Helsinki, Finland, with a subsidiary office in Tokyo, Japan. It has commercial partnerships with insurers and healthcare providers in Finland, the United Kingdom, Japan, and other European and Asian markets. Its risk prediction models are validated using the UK Biobank cohort, giving it access to British population health data (per the firm's disclosures).
How does Nightingale Health's technology differ from traditional blood tests?
Nightingale's test measures a panel of metabolites using NMR spectroscopy, which is more comprehensive than standard clinical blood tests that typically measure a few markers. The platform covers fatty acids, amino acids, and lipoprotein particle concentrations, providing a detailed metabolic fingerprint. This allows risk assessment for multiple chronic diseases from a single sample without requiring fasting (per public scientific publications).
What recent events have shaped Nightingale Health's trajectory?
In November 2024, Nightingale Health announced an integration with Finland's national health data system to provide population-level chronic disease risk screening for healthcare providers. Additionally, the company continues to expand its Asian presence, particularly in Japan, where it has aligned with insurers to offer wellness programs (per press release, November 2024).
Does Nightingale Health accept investments from external LPs?
As a public company listed on the Nasdaq First North Helsinki exchange, Nightingale Health's shares are available for purchase by any investor through brokerage accounts. It does not operate as a fund with limited partners. The firm raised €45 million in its June 2021 IPO (per public filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: